Grifols (GRFS) Shares Outstanding (Diluted Average) (2010 - 2021)
Grifols (GRFS) reported Shares Outstanding (Diluted Average) of $308.87 for Q4 2021, down 71.22% on a YoY basis from $1073.1 in Q4 2020, and down 71.22% quarter-over-quarter from $1073.1 in Q4 2020.
Grifols (GRFS) Shares Outstanding (Diluted Average) (2010 - 2021) Analysis & Trends
Grifols has reported Shares Outstanding (Diluted Average) for 11 years, with the latest figure at $308.87 in Q4 2021.
- For the quarter ending Q4 2021, Shares Outstanding (Diluted Average) fell 71.22% year-over-year to $308.87; the trailing twelve-month figure through Dec 2021 stood at $308.87 (down 71.22% YoY), and the FY2021 full-year result was $308.87, down 71.22% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2021 stood at $308.87, down from $1073.1 in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $1.0 million in Q4 2019, with the low at $308.87 in Q4 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $201932.3 across 5 years, with a median of $560.92 in 2018.
- Annual changes were most pronounced in 2018 — Shares Outstanding (Diluted Average) grew 24.42% — and 2020, when it sank 99.89%.
- Grifols' Shares Outstanding (Diluted Average) stood at $450.82 in 2017, then grew by 24.42% to $560.92 in 2018, then jumped by 179474.59% to $1.0 million in 2019, then sank by 99.89% to $1073.1 in 2020, then plunged by 71.22% to $308.87 in 2021.
- The last three Shares Outstanding (Diluted Average) figures came in at $308.87 (Q4 2021), $1073.1 (Q4 2020), and $1.0 million (Q4 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 895.90 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.45 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.25 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.73 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 308.87 |
| Dec 31, 2020 | 1,073.06 |
| Dec 31, 2019 | 1.01 Mn |
| Jun 30, 2018 | 560.92 |
| Jun 30, 2017 | 450.82 |
| Sep 30, 2016 | 658.55 |
| Jun 30, 2016 | 440.65 |
| Sep 30, 2015 | 656.25 |
| Jun 30, 2015 | 41,995.37 |
| Mar 31, 2015 | 429.34 |
| Sep 30, 2013 | 1,046.78 |
| Jun 30, 2013 | 705.11 |
| Mar 31, 2013 | 356.50 |
| Dec 31, 2012 | 972.67 |
| Sep 30, 2012 | 725.35 |
| Jun 30, 2012 | 501.13 |
| Mar 31, 2012 | 262.26 |
| Dec 31, 2011 | 215.63 |
| Sep 30, 2011 | 254.63 |
| Jun 30, 2011 | 129.46 |